BY MARKETWIRE
-
Dutch biotech company soars: Rumors of discussions with potential buyers
Qiagen rises enormously on Tuesday adhering to reports that the business has actually held conversations with a number of prospective customers.
-
Novo Nordisk has shaken off the downturn after Trump’s tariff attack on Denmark
The Novo Nordisk supply has actually begun the year well in the initial weeks.
-
Analyst sees no impact on long-term outlook from new Genmab data
Genmab’s share cost decrease adhering to brand-new information is an overreaction, claims Mattias Häggblom of Svenska Handelsbanken.
-
Analyst upbeat as US launch of Wegovy tablet drives shares higher
Novo Nordisk shares get on motivating signals from Wegovy tablet rollout, however an elderly expert advises care over very early prescription numbers.
-
Genmab shows promising results again with cancer drug in new Phase 3 study
The Danish firm anticipates to be able to existing information from 2 various other researches later on in 2026.
-
Compounder files lawsuit against Novo Nordisk and Eli Lilly
Neither Novo Nordisk neither Eli Lilly has actually replied to Bloomberg Information’ ask for discuss the legal action.
-
Genmab shows promising results again with cancer drug in new phase 3 study
The Danish firm anticipates to existing information from 2 various other researches with the medicine in mix with various other medicines later on in 2026.
-
Compounder files lawsuit against Novo Nordisk and Eli Lilly
Neither Novo Nordisk nor Eli Lilly has responded to Bloomberg News’ request for comment on the lawsuit.
-
Danske Bank expects promising data from Zealand Pharma
Nonetheless, the financial institution is worried that the future information can be misunderstood.
-
CEO: Zealand Pharma holds unique edge with AI and protected data
Zealand Pharma chief executive officer Adam Steensberg thinks the firm holds a benefit, having actually invested greater than 25 years creating medication prospects for metabolic i…
